PDCD1 and sarcoma: This is very likely explained by a biased patient selection towards off-label anti-PD1 use in sarcoma histologies that are felt to be more immunotherapy responsive based on prior reports.[6, 8–12] Notably, almost half of our cohort (38 of 84, 45%) is represented by NCCN-guideline suggested, “anti-PD1 responsive” histologic subtypes.